title: Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
abstract: Mr 25,000 single-chain Fv (scFv) molecules are rapidly eliminated from the circulation of immunodeficient mice, yielding highly specific retention of small quantities of scFv in human tumor xenografts. We postulated that the specific retention of scFv in tumor could be enhanced by engineering significant increases in the affinity of the scFv for its target antigens. Affinity mutants of the human anti-HER2/neu (c-erbB-2) scFv C6.5 were generated by site-directed mutagenesis, which target the same antigenic epitope with a 320-fold range in affinity (3.2 x 10(-7) to 1.0 x 10(-9) M). In vitro, the Kd of each scFv correlated closely with the duration of its retention on the surface of human ovarian carcinoma SK-OV-3 cells overexpressing HER2/neu. In biodistribution studies performed in scid mice bearing established SK-OV-3 tumors, the degree and specificity of tumor localization increased significantly with increasing affinity. At 24 h after injection, tumor retention of the highest affinity scFv was 7-fold greater than that of a mutant with 320-fold lower affinity for HER2/neu. Because the rapid renal clearance of scFv may blunt the impact of improved affinity on tumor targeting, the distributions were also assayed in the absence of renal clearance (e.g., in mice rendered surgically anephric). In this model, the peak tumor retentions of the two higher affinity scFv approximated that reported previously for IgG targeting the same SK-OV-3 tumors in scid mice with intact kidneys. In contrast, the mutant with the lowest affinity for HER2/neu failed to accumulate in tumor, indicating the presence of an affinity threshold that must be exceeded for active in vivo tumor uptake. These results indicate that affinity can significantly impact the in vivo tumor-specific retention of scFv molecules.
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. gadams@fccc.edu
authors.forename: G P
authors.initials: GP
authors.lastname: Adams
authors.forename: R
authors.initials: R
authors.lastname: Schier
authors.forename: K
authors.initials: K
authors.lastname: Marshall
authors.forename: E J
authors.initials: EJ
authors.lastname: Wolf
authors.forename: A M
authors.initials: AM
authors.lastname: McCall
authors.forename: J D
authors.initials: JD
authors.lastname: Marks
authors.forename: L M
authors.initials: LM
authors.lastname: Weiner
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D000915:Antibody Affinity; D000937:Antigen-Antibody Reactions; D000939:Epitopes / Q000276:immunology; D005260:Female; D006801:Humans; D007128:Immunoglobulin Fragments / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D007135:Immunoglobulin Variable Region / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D007457:Iodine Radioisotopes; D007668:Kidney / Q000502:physiology; D007700:Kinetics; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D016513:Mice, SCID; D016297:Mutagenesis, Site-Directed; D009363:Neoplasm Proteins / Q000276:immunology*; D009368:Neoplasm Transplantation; D009392:Nephrectomy; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D011877:Radionuclide Imaging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
chemical_list: D000939:Epitopes; D007128:Immunoglobulin Fragments; D007135:Immunoglobulin Variable Region; D007457:Iodine Radioisotopes; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases